AAPL350.69+8.32 (+2.43%) ▲|ABBV293.30+1.99 (+0.68%) ▲|ABT110.51+0.58 (+0.53%) ▲|ACN254.37-6.13 (-2.35%) ▼|ADBE237.32-1.98 (-0.83%) ▼|AMAT370.55+37.84 (+11.37%) ▲|AMD508.58+59.54 (+13.26%) ▲|AMGN465.23+4.81 (+1.04%) ▲|AMT189.00+0.21 (+0.11%) ▲|AMZN266.93+7.63 (+2.94%) ▲|AVGO319.48+25.79 (+8.78%) ▲|AXP324.31+3.32 (+1.03%) ▲|BA172.38-1.02 (-0.59%) ▼|BAC50.55+1.13 (+2.29%) ▲|BKNG163.49+2.83 (+1.76%) ▲|BLK1,214.71+35.84 (+3.04%) ▲|BMY62.14+0.00 (+0.00%) ▲|BNY151.23+3.51 (+2.38%) ▲|BRK-B575.25+4.36 (+0.76%) ▲|C121.97+2.92 (+2.45%) ▲|CAT598.88+40.25 (+7.21%) ▲|CL97.94+1.38 (+1.43%) ▲|CMCSA24.51+0.12 (+0.49%) ▲|COF198.58-3.29 (-1.63%) ▼|COP134.47-1.80 (-1.32%) ▼|COST1,066.18+12.62 (+1.20%) ▲|CRM214.94+1.29 (+0.60%) ▲|CSCO98.65+4.80 (+5.11%) ▲|CVS85.25+1.40 (+1.67%) ▲|CVX210.78-1.83 (-0.86%) ▼|DE691.28+19.63 (+2.92%) ▲|DHR235.12+4.87 (+2.12%) ▲|DIS119.12+2.37 (+2.03%) ▲|DUK128.10+0.32 (+0.25%) ▲|EMR169.52+7.17 (+4.42%) ▲|FDX318.84+10.70 (+3.47%) ▲|GD362.07+8.01 (+2.26%) ▲|GE335.54+12.30 (+3.81%) ▲|GEV829.34+55.23 (+7.13%) ▲|GILD169.32+2.43 (+1.46%) ▲|GM89.65+3.49 (+4.05%) ▲|GOOG286.01+2.08 (+0.73%) ▲|GOOGL288.15+3.37 (+1.18%) ▲|GS906.22+40.40 (+4.67%) ▲|HD353.42+9.95 (+2.90%) ▲|HON229.00+8.95 (+4.07%) ▲|IBM246.11+1.11 (+0.45%) ▲|INTC59.37+3.09 (+5.49%) ▲|INTU338.23-3.27 (-0.96%) ▼|ISRG460.56+7.76 (+1.71%) ▲|JNJ282.11+5.89 (+2.13%) ▲|JPM342.08+7.59 (+2.27%) ▲|KO96.03+0.36 (+0.38%) ▲|LIN520.33+5.08 (+0.99%) ▲|LLY1,411.95+57.95 (+4.28%) ▲|LMT588.19+21.11 (+3.72%) ▲|LOW232.10+7.55 (+3.36%) ▲|LRCX221.31+20.87 (+10.41%) ▲|MA655.81+3.11 (+0.48%) ▲|MCD281.44+4.92 (+1.78%) ▲|MDLZ66.44+0.42 (+0.64%) ▲|MDT102.79+0.99 (+0.97%) ▲|META641.37+31.22 (+5.12%) ▲|MMM188.63+3.48 (+1.88%) ▲|MO75.81-0.31 (-0.41%) ▼|MRK148.76+2.03 (+1.38%) ▲|MS187.10+5.66 (+3.12%) ▲|MSFT545.18+14.57 (+2.75%) ▲|MU733.15+43.15 (+6.25%) ▲|NEE86.86-0.09 (-0.10%) ▼|NFLX63.95+0.54 (+0.85%) ▲|NKE39.88+1.29 (+3.34%) ▲|NOW102.76+0.79 (+0.77%) ▲|NVDA178.67-7.97 (-4.27%) ▼|ORCL119.79+3.69 (+3.18%) ▲|PEP141.88+0.54 (+0.38%) ▲|PFE29.23-0.16 (-0.54%) ▼|PG168.32+2.92 (+1.77%) ▲|PLTR169.20+8.82 (+5.50%) ▲|PM193.12-4.76 (-2.41%) ▼|QCOM171.47+6.06 (+3.66%) ▲|RTX196.31+6.78 (+3.58%) ▲|SBUX109.44+4.03 (+3.82%) ▲|SCHW92.73+1.24 (+1.36%) ▲|SO93.57+1.23 (+1.33%) ▲|SPG233.01+4.59 (+2.01%) ▲|T21.80+0.17 (+0.79%) ▲|TMO721.63+26.87 (+3.87%) ▲|TMUS168.71+6.70 (+4.14%) ▲|TSLA378.05+19.83 (+5.54%) ▲|TXN295.73+18.37 (+6.62%) ▲|UBER71.17+2.58 (+3.76%) ▲|UNH397.62+3.47 (+0.88%) ▲|UNP297.01+6.85 (+2.36%) ▲|UPS110.96+2.66 (+2.46%) ▲|USB60.95+1.50 (+2.52%) ▲|V422.16-0.49 (-0.12%) ▼|VZ46.06+0.37 (+0.81%) ▲|WFC85.49+1.55 (+1.85%) ▲|WMT125.66+0.14 (+0.11%) ▲|XOM164.73-1.14 (-0.69%) ▼|AAPL350.69+8.32 (+2.43%) ▲|ABBV293.30+1.99 (+0.68%) ▲|ABT110.51+0.58 (+0.53%) ▲|ACN254.37-6.13 (-2.35%) ▼|ADBE237.32-1.98 (-0.83%) ▼|AMAT370.55+37.84 (+11.37%) ▲|AMD508.58+59.54 (+13.26%) ▲|AMGN465.23+4.81 (+1.04%) ▲|AMT189.00+0.21 (+0.11%) ▲|AMZN266.93+7.63 (+2.94%) ▲|AVGO319.48+25.79 (+8.78%) ▲|AXP324.31+3.32 (+1.03%) ▲|BA172.38-1.02 (-0.59%) ▼|BAC50.55+1.13 (+2.29%) ▲|BKNG163.49+2.83 (+1.76%) ▲|BLK1,214.71+35.84 (+3.04%) ▲|BMY62.14+0.00 (+0.00%) ▲|BNY151.23+3.51 (+2.38%) ▲|BRK-B575.25+4.36 (+0.76%) ▲|C121.97+2.92 (+2.45%) ▲|CAT598.88+40.25 (+7.21%) ▲|CL97.94+1.38 (+1.43%) ▲|CMCSA24.51+0.12 (+0.49%) ▲|COF198.58-3.29 (-1.63%) ▼|COP134.47-1.80 (-1.32%) ▼|COST1,066.18+12.62 (+1.20%) ▲|CRM214.94+1.29 (+0.60%) ▲|CSCO98.65+4.80 (+5.11%) ▲|CVS85.25+1.40 (+1.67%) ▲|CVX210.78-1.83 (-0.86%) ▼|DE691.28+19.63 (+2.92%) ▲|DHR235.12+4.87 (+2.12%) ▲|DIS119.12+2.37 (+2.03%) ▲|DUK128.10+0.32 (+0.25%) ▲|EMR169.52+7.17 (+4.42%) ▲|FDX318.84+10.70 (+3.47%) ▲|GD362.07+8.01 (+2.26%) ▲|GE335.54+12.30 (+3.81%) ▲|GEV829.34+55.23 (+7.13%) ▲|GILD169.32+2.43 (+1.46%) ▲|GM89.65+3.49 (+4.05%) ▲|GOOG286.01+2.08 (+0.73%) ▲|GOOGL288.15+3.37 (+1.18%) ▲|GS906.22+40.40 (+4.67%) ▲|HD353.42+9.95 (+2.90%) ▲|HON229.00+8.95 (+4.07%) ▲|IBM246.11+1.11 (+0.45%) ▲|INTC59.37+3.09 (+5.49%) ▲|INTU338.23-3.27 (-0.96%) ▼|ISRG460.56+7.76 (+1.71%) ▲|JNJ282.11+5.89 (+2.13%) ▲|JPM342.08+7.59 (+2.27%) ▲|KO96.03+0.36 (+0.38%) ▲|LIN520.33+5.08 (+0.99%) ▲|LLY1,411.95+57.95 (+4.28%) ▲|LMT588.19+21.11 (+3.72%) ▲|LOW232.10+7.55 (+3.36%) ▲|LRCX221.31+20.87 (+10.41%) ▲|MA655.81+3.11 (+0.48%) ▲|MCD281.44+4.92 (+1.78%) ▲|MDLZ66.44+0.42 (+0.64%) ▲|MDT102.79+0.99 (+0.97%) ▲|META641.37+31.22 (+5.12%) ▲|MMM188.63+3.48 (+1.88%) ▲|MO75.81-0.31 (-0.41%) ▼|MRK148.76+2.03 (+1.38%) ▲|MS187.10+5.66 (+3.12%) ▲|MSFT545.18+14.57 (+2.75%) ▲|MU733.15+43.15 (+6.25%) ▲|NEE86.86-0.09 (-0.10%) ▼|NFLX63.95+0.54 (+0.85%) ▲|NKE39.88+1.29 (+3.34%) ▲|NOW102.76+0.79 (+0.77%) ▲|NVDA178.67-7.97 (-4.27%) ▼|ORCL119.79+3.69 (+3.18%) ▲|PEP141.88+0.54 (+0.38%) ▲|PFE29.23-0.16 (-0.54%) ▼|PG168.32+2.92 (+1.77%) ▲|PLTR169.20+8.82 (+5.50%) ▲|PM193.12-4.76 (-2.41%) ▼|QCOM171.47+6.06 (+3.66%) ▲|RTX196.31+6.78 (+3.58%) ▲|SBUX109.44+4.03 (+3.82%) ▲|SCHW92.73+1.24 (+1.36%) ▲|SO93.57+1.23 (+1.33%) ▲|SPG233.01+4.59 (+2.01%) ▲|T21.80+0.17 (+0.79%) ▲|TMO721.63+26.87 (+3.87%) ▲|TMUS168.71+6.70 (+4.14%) ▲|TSLA378.05+19.83 (+5.54%) ▲|TXN295.73+18.37 (+6.62%) ▲|UBER71.17+2.58 (+3.76%) ▲|UNH397.62+3.47 (+0.88%) ▲|UNP297.01+6.85 (+2.36%) ▲|UPS110.96+2.66 (+2.46%) ▲|USB60.95+1.50 (+2.52%) ▲|V422.16-0.49 (-0.12%) ▼|VZ46.06+0.37 (+0.81%) ▲|WFC85.49+1.55 (+1.85%) ▲|WMT125.66+0.14 (+0.11%) ▲|XOM164.73-1.14 (-0.69%) ▼|
11.9 C
New York
Tuesday, November 10, 2026

Tag: health

newsFORsourcecompanycontentinformationreleases1IT

Inhaled Insulin Shown as a Safe and Effective Replacement for Standard-of-Care in Children with Type 1 Diabetes

Findings Highlight Potential for Novel Approach to Insulin Delivery in Pediatric Population CHICAGO, June 22, 2025 /PRNewswire/ -- Today, a new study demonstrates inhaled insulin...

ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Elevance Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ELV

NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Elevance Health, Inc. (NYSE: ELV) between April 18, 2024 and October 16, 2024, both dates inclusive (the “Class Period”), of the important July 11, 2025 lead plaintiff deadline.

FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance

Company to also highlight advancements in denials and underpayments management and speak to the measurable impact of RCM technology adoption DENVER, June 22, 2025 /PRNewswire/...

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPG

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. ("PepGen" or the "Company")...

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published...

Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association’s (ADA) 85th Scientific Sessions and published in NEJM.

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing...

CagriSema Demonstrates Significant Weight Loss in Adults with Obesity

Once-weekly medication results in weight loss of up to 22.7% in adults without diabetes and 15.7% in those with type 2 diabetes CHICAGO, June 22,...

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility and actionable intelligence DENVER, June 22, 2025 /PRNewswire/ --...

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs and advancing tech-driven economic growth aligned with Trump administration’s pro-crypto stance. 
Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs and advancing tech-driven economic growth aligned with Trump administration’s pro-crypto stance.

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project as Federal Support for Blockchain Grows

Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and tech-based economic opportunities amid pro-crypto

Jacob Wang Featured in XYZ Media’s “Next Generation of Innovators” for Developing a Self-Actuated, Eco-Friendly Soft Robot for Drug Delivery

LOS ANGELES, June 22, 2025 (GLOBE NEWSWIRE) -- XYZ Media, a leading media company that bridges educational pursuits with technological innovation, is proud to announce the latest feature in its “Next Generation of Innovators” series, a digital campaign celebrating extraordinary young minds developing innovative solutions to global challenges. The latest series highlights Jacob Wang from Bullis Charter School at Los Altos, CA, for engineering a novel self-actuated soft robot that operates without external power sources or electronics, designed with potential for drug delivery.

The American Diabetes Association Announces Winners of the Innovation Challenge to Transform Diabetes Care

This challenge Kickstarts additional investments through the new ADA Innovation Fund CHICAGO, June 21, 2025 /PRNewswire/ -- As the American Diabetes Association® (ADA) celebrates its...

Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes

Common obesity drug reduced the risk of disease progression by 54% CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular...

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

Abvance presents first-in-human data on insulin-glucagon co-dosing in T1D, demonstrating a novel approach to help prevent hypoglycemia

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHealth

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers